BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38648637)

  • 1. Follow the Area Under the Curve Not the Trough Concentration: A Case Study of Tacrolimus Monitoring in a Kidney Transplant Recipient Cotreated With Phenobarbital.
    Izarn O; Morin MP; Ntobe-Bunkete B; Golbin L; Ferrand-Sorre MJ; Tron C; Lemaitre F
    Ther Drug Monit; 2024 Jun; 46(3):285-287. PubMed ID: 38648637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients.
    Pisitkun T; Eiam-Ong S; Chusil S; Praditpornsilpa K; Pansin P; Tungsanga K
    Transplant Proc; 2002 Dec; 34(8):3173-5. PubMed ID: 12493410
    [No Abstract]   [Full Text] [Related]  

  • 3. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation.
    Uchida K; Tominaga Y; Haba T; Katayama T; Matsuoka S; Sato T; Goto N; Takeda A; Morozumi K; Takagi H
    Transplant Proc; 2002 Aug; 34(5):1736-7. PubMed ID: 12176556
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic drug monitoring of once-daily tacrolimus (Advagraf) in a gastrectomized kidney transplant recipient.
    Ma TK; Chow KM; Kwan BC; Leung CB; Szeto CC; Li PK
    Nephrology (Carlton); 2017 Feb; 22(2):184. PubMed ID: 28064453
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of tacrolimus in adult renal transplant recipients.
    Naik P; Madhavarapu M; Mayur P; Nayak KS; Sritharan V
    Drug Metabol Drug Interact; 2012; 27(3):151-5. PubMed ID: 23089531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients.
    Jørgensen K; Povlsen J; Madsen S; Madsen M; Hansen H; Pedersen A; Heinsvig EM; Poulsen J
    Nephrol Dial Transplant; 2002 Aug; 17(8):1487-90. PubMed ID: 12147799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients.
    Sato S; Fuchinoue S; Tojimbara T; Fujita S; Nakajima I; Agishi T; Hayashi T; Teramura Y; Fujita E; Iwasaki K
    Transplant Proc; 1998 Jun; 30(4):1274-5. PubMed ID: 9636517
    [No Abstract]   [Full Text] [Related]  

  • 8. Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients.
    Jørgensen KA; Povlsen JV; Madsen S; Madsen M; Hansen HE; Pedersen AR; Heinsvig EM; Poulsen JH
    Transplant Proc; 2002 Aug; 34(5):1721-2. PubMed ID: 12176551
    [No Abstract]   [Full Text] [Related]  

  • 9. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients.
    Toda F; Tanabe K; Ito S; Shinmura H; Tokumoto T; Ishida H; Toma H
    Transplant Proc; 2002 Aug; 34(5):1733-5. PubMed ID: 12176555
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic drug monitoring of tacrolimus early after liver transplantation.
    Braun F; Peters B; Schütz E; Lorf T; Undre N; Oellerich M; Ringe B
    Transplant Proc; 2002 Aug; 34(5):1538-9. PubMed ID: 12176473
    [No Abstract]   [Full Text] [Related]  

  • 12. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve.
    Balbontin FG; Kiberd B; Squires J; Singh D; Fraser A; Belitsky P; Lawen J
    Transplant Proc; 2003 Nov; 35(7):2445-8. PubMed ID: 14611982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.
    McAlister VC; Mahalati K; Peltekian KM; Fraser A; MacDonald AS
    Ther Drug Monit; 2002 Jun; 24(3):346-50. PubMed ID: 12021624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.
    Oellerich M; Armstrong VW; Schütz E; Shaw LM
    Clin Biochem; 1998 Jul; 31(5):309-16. PubMed ID: 9721427
    [No Abstract]   [Full Text] [Related]  

  • 16. Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.
    Frassetto LA; Tan-Tam CC; Barin B; Browne M; Wolfe AR; Stock PG; Roland M; Benet LZ
    Transplantation; 2014 Mar; 97(6):702-7. PubMed ID: 24389906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
    Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
    J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
    Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
    Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients.
    Hesse CJ; Baan CC; Balk AH; Metselaar HJ; Weimar W; van Gelder T
    Transplant Proc; 2002 Nov; 34(7):2988-90. PubMed ID: 12431679
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient.
    Quirós-Tejeira RE; Chang IF; Bristow LJ; Karpen SJ; Goss JA
    Pediatr Transplant; 2005 Dec; 9(6):792-6. PubMed ID: 16269053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.